Methyl 3-(Cyanomethyl)Benzoate

68432-92-8

Chenglian Pharmaceutical is an innovative high-tech phar maceutical enterprise that is market-oriented and realizes industrial development t"hrough R&D innovation and technology transformation.

key word:

Pharmaceutical innovative

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry fin§ance platform company integrating pharmaceutical, intelligent medical, bio pha rmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucaul÷t reaction, nitration reaction, sulfonation reaction, hydrogenation re♦action, fluorination reaction, chlorination reactio<n, bromination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by MerckΩ. In October 2006, Sitagliptin phosphate Januvia was approved by FD≤A as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The chara§cteristics of this drug are that it can stimulate insulin secretion wh‌ile reducing hunger without causing weight gain. Hypoglycemia and edema will not occur, an≥d it is suitable for diabetic patients with poor blood glucose control and frequent hypoglyce'mia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterp rise that is market-oriented and realizes industrial d±evelopment through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of t≠he most important products for the treatment of arthritis. It is well tolerated and hasβ a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukot↑riene receptor antagonists. In clinical application , it has good therapeutic effect on atopic asthma and other types of bronchial↕ asthma, and the market prospect is huge. In the major category of asthma drugs, le'ukotriene receptor antagonists have the fastest growing  market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterp≤rise that is market-oriented and realizes industrial development t>hrough R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drugγ approved by FDA for Alzheimer's disease in the Unite∞d States. Its treatment reaches the target dose and has low toxic and side efφfects. It has been widely recognized by our medical community, and good tolerance★ is its biggest advantage. In October 1999, Donepezil was launched ↕in China under the trade name "Aricept", which is the main chemical drug agains✘t Alzheimer's disease. At present, CFDA has approved a number of domestic enterprises to< produce donepezil preparations, the main dosage forms ↔are tablets, capsules, dispersive tablets, oral disi•ntegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Api​xaban (Eliquis, Bristol-Myers Squibb/Pfizer), a direct oral facto​r Xa inhibitor, was approved for use in the 27 EU member states. The world's first dru​g approved to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or kn'ee replacement. From June 2019 to June 2020, the annual sales of apixaban products o verseas reached about $15.4 billion, with a year-on-year✘ growth of nearly 32%, and the API consumption reached about 2‌3,960 kg, with a year-on-year growth of about 28%. Compared with its main competit↕or, Rivaroxaban, the drug's annual overseas sales are  about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical ♥enterprise that is market-oriented and realizes industrial development thr ough R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On Dπecember 29, 2004, it was approved by FDA for the treatment of refractory ¶or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical  enterprise that is market-oriented and realizes industrial development through R&D πinnovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working day£s). If you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technolog♣y Co., Ltd.